Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study (Preprint)
Authors:
- Katharina BrusniakKBKatharina Brusniak
- Manuel FeisstMFManuel Feisst
- Linda SebestenyLSLinda Sebesteny
- Andreas HartkopfAHAndreas Hartkopf
- Joachim GrafJGJoachim Graf
- Tobias EnglerTETobias Engler
- Andreas SchneeweissASAndreas Schneeweiss
- Markus WallwienerMWMarkus Wallwiener
- Thomas Maximilian DeutschTDThomas Maximilian Deutsch
Preprint
- 15 November 2020
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Health-related quality of life (HRQoL) is used to evaluate the treatment of metastatic breast cancer. In a long-term therapy setting, HRQoL can be used as an important benchmark for treatment success. With the help of digital apps, HRQoL monitoring can be extended to more remote areas and be administered on a more frequent basis. OBJECTIVE This study aims to evaluate 3 common HRQoL questionnaires in metastasized breast cancer in terms of TTD in a digital, web-based setting. We further aim to examine the development of the HRQoL in different systemic treatment groups in each of these evaluation instruments. METHODS A total of 192 patients with metastatic breast cancer were analyzed in this bicentric prospective online cohort study at two German university hospitals. Patients completed questionnaires on HRQoL (EuroQol Visual Analog Scale [EQ-VAS], EuroQol 5 Dimension 5 Level [EQ-5D-5L], European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 item [EORTC QLQ-C30]) via an online platform over a 6-month period. Treatment schedules and medical history were retrieved from medical records. Unadjusted Cox regression analysis on treatment-related factors was performed. We conducted subgroup analyses in regard to TTD events between different treatments. RESULTS The EQ-VAS showed a higher rate of deterioration after 8 weeks (84/179, 46.9%) than the EQ-5D-5L (47/163, 28.8%) and EORTC QLQ-C30 (65/176, 36.9%). Unadjusted Cox regression revealed significant connections between known metastases in the liver (P=.03, HR 1.64, 95% CI 1.06-2.52) and pleura (P=.04, HR 0.42, 95% CI 0.18-0.96) in the EQ-VAS. Significant relations between EQ-VAS events and single EQ-5D-5L items and the EQ-5D-5L summary score were demonstrated. All treatment groups significantly differed from the CDK4/6 inhibition subgroup in the EQ-VAS. CONCLUSIONS Compared to the EQ-5D-5L and QLQ-C30, the EQ-VAS showed a higher rate of deterioration after 8 weeks. Significant connections to certain metastatic locations were only detected in the EQ-VAS. The EQ-VAS is capable of reflecting the distinctive HRQoL profiles of different systemic treatments as well as the different aspects of HRQoL presented in the EQ-5D-5L. TTD with the EQ-VAS is an adequate mean of examining longitudinal development of HRQoL among breast cancer patients.Keywords
All Related Versions
- Published version: JMIR Cancer, 7 (4), e25776.
This publication has 49 references indexed in Scilit:
- Epidemiology of Breast Cancer - Current Figures and TrendsGeburtshilfe und Frauenheilkunde, 2013
- Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort studyQuality of Life Research, 2012
- Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast CancerThe Oncologist, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic reviewAnnals of Oncology, 2010
- Responsiveness of the EQ-5D in breast cancer patients in their first year after treatmentHealth and Quality of Life Outcomes, 2009
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- Impact of chemotherapy beyond the first line in patients with metastatic breast cancerBreast Cancer Research and Treatment, 2007
- Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled TrialJournal of Clinical Oncology, 2004
- Clinical understanding and clinical implications of response shiftSocial Science & Medicine, 1999